Print

Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain  
8/18/2009 8:55:11 AM

Emeryville, Calif., Aug. 18 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

"Collaborating with the U.S. Naval Health Research Center, with its leadership in medicine and its seminal work in discovering the novel influenza A/H1N1 virus, will significantly advance Adamas' efforts to develop TCAD therapy in response to the influenza pandemic," said Gregory Went, Ph.D., Chief Executive Officer and Chairman of Adamas. "We look forward to partnering with the Naval Health Research Center to generate data that further support the potential use of TCAD therapy for the military, healthcare workers and general public when faced with the global threat of influenza A outbreaks."

About TCAD

About Naval Medical Research, San Diego

About Adamas

SOURCE Adamas Pharmaceuticals, Inc.

CONTACT: Kimberly Kraemer, Corporate Communications of Adamas
Pharmaceuticals, +1-415-939-9033; or Aimee Corso of WeissComm Partners,
+1-310-780-2661, for Adamas Pharmaceuticals

Web site: http://www.adamaspharma.com/


//-->